Organizations often implement the visible components of RBQM including CTQs, risk assessments, KRIs, dashboards and governance, without addressing the behaviors and professional capabilities needed to make the model work. Effective RBQM requires teams to think critically, challenge assumptions, interpret signals in context and make proportionate decisions when information is incomplete.

Explore how leaders can apply change-management principles to embed risk-based thinking into everyday clinical development activities. Move beyond procedural compliance to build a culture in which judgment, accountability, cross-functional collaboration and continuous learning drive participant protection and reliable trial results.

• Shift teams from activity-based compliance toward decisions focused on what is critical to quality
• Strengthen critical thinking, systems thinking and risk-based judgment
• Build confidence in making proportionate decisions under uncertainty
• Encourage constructive challenge and psychological safety when risks or assumptions need to be questioned
• Improve communication, influence, and decision-making across sponsor, CRO and functional boundaries
• Reinforce new behaviors through leadership modeling, coaching, governance, and meaningful performance measures
• Evaluate RBQM adoption through decision quality, consistency, response time and effectiveness—not training completion alone

Can your team clearly explain how risks, signals, decisions, and interventions connect across the life of a study? During this case study, get inside an inspection scheduled for five days that concluded in only 3.5. Discover how the team built a coherent quality narrative, demonstrated the rationale behind its RBQM decisions, responded to inspector questions, and connected supporting evidence without overwhelming the conversation with disconnected documentation. Learn what strengthened inspector confidence, what challenged the team, and how to build an inspection story that can withstand scrutiny.

• Construct a clear inspection narrative connecting critical-to-quality factors, identified risks, monitoring activities, interventions, and documented outcomes
• Demonstrate the rationale behind RBQM decisions, not simply the existence of procedures, dashboards, or documentation
• Prepare study teams to respond consistently and confidently when inspectors probe beyond planned presentations
• Identify documentation gaps or disconnected evidence that could weaken an otherwise effective quality story

A critical-to-quality factor only matters when it changes how the trial is designed, managed and monitored. Follow one real CTQ from protocol assumptions through signal review, intervention and final evaluation.

• Establish why the factor was truly critical to the trial
• Convert the CTQ into controls, indicators and escalation criteria
• Assign ownership across functions and external partners
• Adapt the strategy as trial conditions and evidence change
• Evaluate whether the original controls protected what mattered

When everything is labeled critical, your team loses the ability to focus. Work through a complex trial scenario and decide which risks genuinely threaten participant protection or result reliability.

• Separate CTQs from routine operational concerns
• Challenge assumptions driving initial prioritization
• Determine which risks require prevention, detection or acceptance
• Account for participant burden, protocol complexity and site feasibility
• Remove unnecessary controls before they weaken execution

A crowded dashboard can create the appearance of control while hiding the signals that matter. Hear how one organization challenged its indicators, recalibrated its thresholds, and built a more actionable KRI portfolio.

• Identify indicators that produced activity without changing decisions
• Separate predictive signals from lagging performance measures
• Recalibrate thresholds using trial-specific context
• Reduce duplication across functions and platforms
• Measure whether the revised approach improved intervention

Participants will receive a simulated trial file containing competing signals, incomplete records and uncomfortable inconsistencies. Teams must reconstruct the quality story and defend their decisions before a mock inspection panel.

• Trace CTQs through controls, signals, reviews and actions
• Explain why certain risks received greater attention
• Defend decisions to intervene, monitor further or take no action
• Identify gaps between documented procedure and actual execution
• Build a coherent narrative from trial design through oversight

The FDA has published, in plain language, what actually went wrong in the form of warning letters. Every warning letter and inspection finding since 2021 is public. These are not hypotheticals. They are documented failures at real sites in real studies, and they describe exactly what inspectors looked for and did not find. Work through a set of those findings one at a time. Identify what analysis would have caught it and what data that analysis requires. Each finding is then mapped against the four-level maturity model from the eClinical Forum audit trail analytics paper, to show what catching it would look like in a solution that actually works.

Clinical trial data increasingly flows through systems operated by CROs, technology vendors and other service providers, but delegation of the system does not mean delegation of sponsor accountability. Follow a case where a critical data concern forces the sponsor to determine whether its oversight model can actually detect, investigate and defend failures occurring inside delegated systems.